19 Nov 2012, BioSpectrum Bureau , BioSpectrum
Singapore: Promega opened a new facility in Shanghai for its China operations. The new site for Shanghai Promega Biological Products replaces an existing molecular biology reagent production site and provides additional research, development and cGMP manufacturing capabilities for molecular diagnostics products for the Chinese market.
The US-based company is a leader in providing innovative solutions and technical support to the life sciences industry. The company's 2,500 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification.
Since its purchase in June of this year, the building in Shanghai has been equipped for manufacturing molecular biology and molecular diagnostic reagents. Under General Manager Mr Tom Duan, a team of 40 scientists, technicians and administrators will begin operations in the new facility in the next few weeks.
"China is an integral part of Promega's manufacturing and business operations. In 1985, Promega and two Chinese partners established Sino-American Biotechnology (SABC), the first China-US biotech joint venture in China," said Mr Bill Linton, CEO,Promega. "This recent investment in the new Shanghai cGMP manufacturing facility represents Promega's continued commitment to life science in China." Among its 15 global branches, Promega also has a sales and marketing branch in Beijing.
The new facility, called Shanghai Promega Life Science Center, is one of five Promega manufacturing sites worldwide. Together these facilities manufacture biological and chemical reagents and instruments used in both life science research and molecular diagnostics. Promega products are manufactured under certified quality systems that meet the requirement of ISO 9001 or ISO 13485, depending on product intended use.